The UK-based biotechnology company Freeline recently announced that the first U.S. patient has been dosed in its Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for the treatment of hemophilia B. FLT180a is developed with the company’s…
In advance of World Hemophilia Day this year (April 17), NHF sat down with historian Dr. Helen Rappaport to learn more about how hemophilia impacted the Romanov family, and its lasting impact on world…
FOR IMMEDIATE RELEASE
Media Contact:
Ilana Ostrin
iostrin@hemophilia.org
212-328-3769
April 17, 2022
STATEMENT FROM DR. LEONARD A. VALENTINO (NHF CEO) ON WORLD HEMOPHILIA DAY
On World Hemophilia Day…